Literature DB >> 2880291

A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease.

S Tsuji, P V Choudary, B M Martin, B K Stubblefield, J A Mayor, J A Barranger, E I Ginns.   

Abstract

To search for a genetic marker for type 2 Gaucher's disease (acute neuronopathic form), we compared the nucleotide sequence of a cloned glucocerebrosidase gene from a patient with Gaucher's disease with a normal gene. We found only a single base substitution (T----C) in exon X. This mutation results in the substitution of proline for leucine in position number 444 and produces a new cleavage site for the NciI restriction endonuclease. We analyzed NciI enzymatic digests of genomic DNA from 20 patients with type 1, 5 with type 2, and 11 with type 3 Gaucher's disease, and 29 normal controls for a restriction-fragment-length polymorphism (RFLP). Four of 5 patients with type 2 disease and all 11 with type 3 disease had at least one allele with the mutation. Two of 5 patients with type 2 disease and 7 of 11 with type 3 were homozygous for this mutation. Only 4 of 20 patients with type 1 Gaucher's disease had the mutant allele and were heterozygous for it. None of the 29 normal controls had the mutant allele. The high frequency of this mutation (444leucine----proline) in patients with neuronopathic Gaucher's disease, detectable by the NciI RFLP, may be of value in the identification of patients who will have the neurologic sequelae of Gaucher's disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2880291     DOI: 10.1056/NEJM198703053161002

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  88 in total

1.  Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes.

Authors:  Zakarya El-Morsy; Mohamed T Khashaba; Othman El-Sayed Soliman; Sohier Yahia; Dina Abd El-Hady
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  Gaucher's disease.

Authors:  V Barbour; M E Wood
Journal:  J R Soc Med       Date:  1992-06       Impact factor: 5.344

3.  Familial hypercholesterolemia associated with severe hypoalphalipoproteinemia in a Moroccan family.

Authors:  Karima Ait Chihab; Rachif Chater; Ana Cenarro; Anass Kettani; Sergio Castillo; Mohamed Loutfi; Josep Ribalta; Ahmed Adlouni; Miguel Pocovi; Mariame El Messal
Journal:  J Genet       Date:  2007-08       Impact factor: 1.166

4.  Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease.

Authors:  Benjamin Liou; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2009-02-13       Impact factor: 4.797

5.  Linkage of the PvuII polymorphism with the common Jewish mutation for Gaucher disease.

Authors:  A Zimran; T Gelbart; E Beutler
Journal:  Am J Hum Genet       Date:  1990-05       Impact factor: 11.025

6.  The clinical, molecular, and pathological characterisation of a family with two cases of lethal perinatal type 2 Gaucher disease.

Authors:  E Sidransky; N Tayebi; B K Stubblefield; W Eliason; A Klineburgess; G P Pizzolato; J N Cox; J Porta; A Bottani; C D DeLozier-Blanchet
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

Review 7.  Pathogenesis-based therapies in ichthyoses.

Authors:  Joey E Lai-Cheong; Peter M Elias; Amy S Paller
Journal:  Dermatol Ther       Date:  2013 Jan-Feb       Impact factor: 2.851

8.  A new glucocerebrosidase-gene missense mutation responsible for neuronopathic Gaucher disease in Japanese patients.

Authors:  H Kawame; Y Eto
Journal:  Am J Hum Genet       Date:  1991-12       Impact factor: 11.025

9.  Complex alleles of the acid beta-glucosidase gene in Gaucher disease.

Authors:  T Latham; G A Grabowski; B D Theophilus; F I Smith
Journal:  Am J Hum Genet       Date:  1990-07       Impact factor: 11.025

10.  Only three mutations account for almost all defective alleles causing adenine phosphoribosyltransferase deficiency in Japanese patients.

Authors:  N Kamatani; M Hakoda; S Otsuka; H Yoshikawa; S Kashiwazaki
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.